ライフサイエンスコーパス: choledocholithiasis

1 emoval became the primary method of managing choledocholithiasis.

2 MRCP has a high sensitivity in detecting choledocholithiasis.

3 hy-based treatment of patients with possible choledocholithiasis.

4 pproach based on preoperative probability of choledocholithiasis.

5 The major cause for obstructive jaundice was choledocholithiasis.

6 for patients presenting to the hospital with choledocholithiasis.

7 ecystectomy for malignancy, pancreatitis, or choledocholithiasis.

8 ulfill the criteria for a high likelihood of choledocholithiasis.

9 e clinical criteria for a high likelihood of choledocholithiasis.

10 reformations, for biliary duct narrowing and choledocholithiasis.

11 the detection of biliary duct narrowing and choledocholithiasis.

12 with balloon dilation for the management of choledocholithiasis.

13 fluid, and (e) common bile duct size and/or choledocholithiasis.

14 e, noninvasive modality for the detection of choledocholithiasis.

15 elical CT is useful for evaluating suspected choledocholithiasis.

16 ting with pancreatitis, and risk factors for choledocholithiasis.

17 Of the patients who underwent ERCP for choledocholithiasis, 41.2% underwent early CCY, 10.9% un

18 inesia (65.3%), acute cholecystitis (26.6%), choledocholithiasis (5.7%), or gallstone pancreatitis (2

19 d into two groups based on the likelihood of choledocholithiasis according to the clinical predictors

20 ions were more likely at urban hospitals for choledocholithiasis (adjusted odds ratio, aOR, 2.94, 95%

21 there are an average of 26158 patients with choledocholithiasis admitted in the United States each y

22 The occurrence of choledocholithiasis among patients in the four groups we

23 tic imaging because of improved detection of choledocholithiasis and alternative causes of biliary ob

24 Choledocholithiasis and cholangitis are common complicat

25 t Sample was used to identify discharges for choledocholithiasis and cholangitis between 2005 and 201

26 Hospitalizations for choledocholithiasis and cholangitis have increased betwe

27 , management, and outcomes for patients with choledocholithiasis and cholangitis.

28 consequence of the endoscopic management of choledocholithiasis and the continuing controversy over

29 From 189,362 unweighted discharges for choledocholithiasis and/or cholangitis, there was an inc

30 cer, biliary disease (eg, cholelithiasis and choledocholithiasis), and jejunojejunal anastomotic issu

31 d therapy for malignant biliary obstruction, choledocholithiasis, and biliary complications post-live

32 The baseline characteristics, presence of choledocholithiasis, and complications were compared bet

33 r, in the evaluation of pancreatic cysts and choledocholithiasis, and in performing therapeutic proce

34 rtality significantly decreased annually for choledocholithiasis (aOR 0.90, 95% CI 0.88 to 0.93) and

35 n rural and urban centers was comparable for choledocholithiasis (aOR 1.16, 95% CI 0.89 to 1.52) and

36 tis, there was an increase in discharges for choledocholithiasis (APC 2.3%, 95% confidence intervals,

37 The management and diagnosis of choledocholithiasis are discussed, as well as endoscopic

38 modality for the diagnosis and resolution of choledocholithiasis before LC.

39 The probability of choledocholithiasis can be accurately assessed based on

40 Choledocholithiasis can be managed laparoscopically in e

41 and evaluation and management of persistent choledocholithiasis can help guide clinicians in diagnos

42 be performed for urgent indications, such as choledocholithiasis, cholangitis, and some cases of gall

43 o symptomatic cholelithiasis, cholecystitis, choledocholithiasis, cholangitis, or biliary pancreatiti

44 chronic biliary tract inflammation owing to choledocholithiasis, cholelithiasis, or primary sclerosi

45 ruled out, such as hepatobiliary malignancy, choledocholithiasis, cholestatic forms of viral hepatiti

46 pecifically, the diagnosis and management of choledocholithiasis, complications of biliary endoscopy

47 The overall use of CBDE for patients with choledocholithiasis decreased from 39.8% of admissions i

48 enign biliary stricture, papillary stenosis, choledocholithiasis, extrinsic compression from pancreat

49 Stratification of risks for choledocholithiasis facilitates patient management with

50 r groups based on the level of suspicion for choledocholithiasis (group I, extremely high; group 2, h

51 thermore, an optimal management strategy for choledocholithiasis has yet to be defined.

52 gnoses of acute cholecystitis, pancreatitis, choledocholithiasis, hematologic disorders, and emergent

53 nefits of LCBDE+LC over ERCP+LC for managing choledocholithiasis, if current trends continue, CBDE ma

54 Endoscopic management of choledocholithiasis in gallstone pancreatitis, a newer a

55 cholangiopancreatography (ERCP) by excluding choledocholithiasis in patients with acute pancreatitis

56 red with 264 controls with cholelithiasis or choledocholithiasis in the absence of cancer and with 12

57 cement positions, the timing and approach to choledocholithiasis in the context of anticipated cholec

58 evaluate secular trends in the management of choledocholithiasis in the United States and to compare

59 The choledocholithiasis management algorithm proposed by the

60 tricture (n = 12), choledochal cyst (n = 5), choledocholithiasis (n = 3), idiopathic cholangitis (n =

61 rategies for gallstone disease with possible choledocholithiasis: noncontrast MR cholangiopancreatogr

62 For detecting choledocholithiasis, observer 1 had a sensitivity of 77.

63 biliary obstruction, altered GI anatomy, and choledocholithiasis on CT scan were excluded.

64 h sclerosing cholangitis, liver transplants, choledocholithiasis, or portosystemic shunts.

65 In high-probability choledocholithiasis patients with a negative CT, the EUS

66 44 patients received EUS first, and ERCP if choledocholithiasis present (EUS-first group).

67 Diagnosis of choledocholithiasis requires clinical manifestations and

68 S: Cholecystectomy (CCY) after an episode of choledocholithiasis requiring endoscopic retrograde chol

69 s with an intermediate or high likelihood of choledocholithiasis requiring therapeutic ERCP.

70 85, and 0.98 for strictures, dilatation, and choledocholithiasis, respectively.

71 studied patients with a primary diagnosis of choledocholithiasis that were included in the National I

72 ients who meet high probability criteria for choledocholithiasis to receive endoscopic retrograde cho

73 ospital length of stay between patients with choledocholithiasis treated with endoscopic retrograde c

74 (aged 18-94 years) with clinically suspected choledocholithiasis underwent unenhanced helical CT imme

75 tterns for performance of CCY after ERCP for choledocholithiasis using data from 3 large states and e

76 the common bile duct to rule out concomitant choledocholithiasis varies and should be tailored to lev

77 In 18 (19%) of 94 patients, choledocholithiasis was detected at reference examinatio

78 Choledocholithiasis was detected in 43 of 440 patients (

79 analysis of >4500 patients hospitalized with choledocholithiasis, we found that CCY was not performed

80 Patients with cholecysto-choledocholithiasis were randomized either to LERV or to

81 tal of 604 patients with high probability of choledocholithiasis were screened and 104 patients were

82 tation, and intraductal filling defects (all choledocholithiasis) were 86% (40 of 47) and 94% (45 of

83 Overall, 51 patients (49.0%) had choledocholithiasis, which did not justify the risk of d

84 ed data from 4516 patients hospitalized with choledocholithiasis who underwent ERCP.

85 Patients with suspected choledocholithiasis who underwent EUS between June 2009